Literature DB >> 24385386

Management of hypercholesterolemia in children.

Marjet J A M Braamskamp1, Barbara A Hutten, Albert Wiegman, John J P Kastelein.   

Abstract

Cardiovascular disease (CVD) remains the leading cause of death and morbidity in our society. One of the major risk factors for CVD is hypercholesterolemia. Hypercholesterolemia in children can be caused by a hereditary disorder or can be secondary to other diseases or drugs. In order to prevent CVD later in life, children with hypercholesterolemia should be identified and treated as early as possible. Currently, several different screening strategies have been developed, using either universal screening or case finding to search for children at risk. Once those children are identified, the first step in treatment is lifestyle adjustment. If cholesterol levels remain elevated, the drugs of first choice are statins. Other pharmacological options are ezetimibe or bile acid sequestrants. These agents have all proven to be safe and effective in lowering low-density lipoprotein cholesterol levels and improving surrogate markers of CVD. However, there is a need for long-term follow-up studies to answer the question as to whether it is safe to initiate treatment at a young age to prevent CVD later in life.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24385386     DOI: 10.1007/s40272-013-0060-2

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.930


  60 in total

Review 1.  A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia.

Authors:  H J Avis; M N Vissers; E A Stein; F A Wijburg; M D Trip; J J P Kastelein; B A Hutten
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-06-14       Impact factor: 8.311

2.  Family history evaluation as a predictive screen for childhood hypercholesterolemia. Pediatric Practice Research Group.

Authors:  T C Griffin; K K Christoffel; H J Binns; P A McGuire
Journal:  Pediatrics       Date:  1989-08       Impact factor: 7.124

3.  Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia.

Authors:  N J Stone; R I Levy; D S Fredrickson; J Verter
Journal:  Circulation       Date:  1974-03       Impact factor: 29.690

Review 4.  Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia.

Authors:  Caroline M Perry
Journal:  Paediatr Drugs       Date:  2010-04-01       Impact factor: 3.022

Review 5.  Statin use during pregnancy: a systematic review and meta-analysis.

Authors:  D Meeike Kusters; Hajar Hassani Lahsinoui; Joris A M van de Post; Albert Wiegman; Frits A Wijburg; John J P Kastelein; Barbara A Hutten
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-03

6.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Authors:  C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes
Journal:  Lancet       Date:  2005-09-27       Impact factor: 79.321

7.  Cholesterol screening and management in children and young adults should start early--NO!

Authors:  Alan R Schroeder; Rita F Redberg
Journal:  Clin Cardiol       Date:  2012-11       Impact factor: 2.882

8.  Association of physical activity with vascular endothelial function and intima-media thickness.

Authors:  Katja Pahkala; Olli J Heinonen; Olli Simell; Jorma S A Viikari; Tapani Rönnemaa; Harri Niinikoski; Olli T Raitakari
Journal:  Circulation       Date:  2011-10-03       Impact factor: 29.690

9.  Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

Authors:  Frederick J Raal; Raul D Santos; Dirk J Blom; A David Marais; Min-Ji Charng; William C Cromwell; Robin H Lachmann; Daniel Gaudet; Ju L Tan; Scott Chasan-Taber; Diane L Tribble; Joann D Flaim; Stanley T Crooke
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

10.  Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine.

Authors:  R J West; J K Lloyd; J V Leonard
Journal:  Lancet       Date:  1980-10-25       Impact factor: 79.321

View more
  1 in total

1.  Longitudinal evaluation of endothelial markers in children and adolescents with familial hypercholesterolemia.

Authors:  Patrizia Bruzzi; Barbara Predieri; Simona Madeo; Francesca Lami; Lorenzo Iughetti
Journal:  Acta Biomed       Date:  2021-11-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.